-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220

Benzinga·11/03/2026 11:38:12
Listen to the news
Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $246 to $220.